Carter's Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Carter's, Inc. (CRI) is set to report Q3 earnings on October 27, with analysts forecasting a significant year-over-year EPS decline to $0.74 from $1.64, despite an expected revenue increase to $773.09 million. The company recently adopted a limited duration stockholder rights plan after RWWM acquired a 16.86% stake, and its shares closed up 1.8% at $32.35 on Friday. Analyst sentiment is varied, with recent price target adjustments ranging from $26 to $45, reflecting mixed outlooks ahead of the earnings release.

Analysis

Carter's, Inc. (CRI) is poised to report Q3 earnings with a significant projected year-over-year EPS decline to $0.74 from $1.64, despite an anticipated revenue increase to $773.09 million from $758.46 million. This mixed financial outlook is set against a backdrop of recent corporate governance developments, specifically the adoption of a limited duration stockholder rights plan following RWWM's rapid accumulation of a 16.86% stake.

Shares of CRI closed up 1.8% at $32.35 on Friday, yet the overall market sentiment is moderately negative with a cautious tone, as indicated by a sentiment score of -0.5. Analyst ratings reflect this uncertainty, with recent price target adjustments showing divergence: UBS cut its target to $26, Wells Fargo boosted to $28, and Citigroup slashed its target to $45.

The combination of declining EPS forecasts, an activist investor stake, and varied analyst sentiment creates a complex investment thesis for CRI. The upcoming earnings release will be crucial in providing clarity on the operational drivers behind the EPS decline and management's strategy in response to the activist pressure and stockholder rights plan.

Key Decisions for Investors

• Investors should closely monitor the Q3 earnings report for detailed insights into the drivers of the projected EPS decline and management's forward guidance.
• Evaluate the long-term implications of the RWWM activist stake and the adopted stockholder rights plan on corporate strategy and potential shareholder value.
• Consider the wide range of analyst price targets and the moderately negative sentiment, suggesting a lack of clear consensus on CRI's valuation and future trajectory.